Boiron (FRA:BON) FCF Margin % : 2.46% (As of Jun. 2024)

View and export this data going back to . Start your Free Trial

What is Boiron FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Boiron's Free Cash Flow for the six months ended in Jun. 2024 was €5.6 Mil. Boiron's Revenue for the six months ended in Jun. 2024 was €228.3 Mil. Therefore, Boiron's FCF Margin % for the quarter that ended in Jun. 2024 was 2.46%.

As of today, Boiron's current FCF Yield % is 5.86%.

The historical rank and industry rank for Boiron's FCF Margin % or its related term are showing as below:

FRA:BON' s FCF Margin % Range Over the Past 10 Years
Min: 2.39 Med: 7.92 Max: 12.69
Current: 5.14

During the past 13 years, the highest FCF Margin % of Boiron was 12.69%. The lowest was 2.39%. And the median was 7.92%.

FRA:BON's FCF Margin % is ranked better than
61.63% of 972 companies
in the Drug Manufacturers industry
Industry Median: 0.955 vs FRA:BON: 5.14

Boiron FCF Margin % Historical Data

The historical data trend for Boiron's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boiron FCF Margin % Chart

Boiron Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

2.39

9.26

2.83

7.51

5.57

Boiron Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
FCF Margin %	Get a 7-Day Free Trial															11.92	3.43	3.48	7.55	2.46

Competitive Comparison of Boiron's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Boiron's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Boiron's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Boiron's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Boiron's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Boiron FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Boiron's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	27.466	/	493.248
	=	5.57 %

Boiron's FCF Margin for the quarter that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	5.622	/	228.348
	=	2.46 %

Boiron FCF Margin % Related Terms

Thank you for viewing the detailed overview of Boiron's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Boiron Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Boiron SA (FRA:BON) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

0DTF:UK BOI:France BON:Germany

Address

2, Avenue de l’Ouest Lyonnais No. 039, Messimy, FRA, 69510

Website

http://www.boiron.com

Boiron SA is a drug manufacturer that focuses on homeopathic products. The company's revenue is roughly split between its nonproprietary homeopathic medicines and products in its over-the-counter specialties category. Boiron's nonproprietary medicines are generic products that do not refer to any therapeutic indication, while the specialties category includes first-resort products provided in tablet form, are bottled to use as drops, syrups, or ointments. Geographical segments are France, Europe, North America, and other countries. It generates a majority of revenue from France. The company's products include Oscillococcinum, Stodal and Stodaline, Arnigel, Camilia, Sedatif PC, Coryzalia, Homeoptic, and Homeovox.